Boston, MA, 09/04/2013 (nysepost) – Pfizer Inc. (NYSE:PFE) invites shareholders and the citizens to heed a webcast of a conversation with Frank D’Amelio, Executive VP, Business Operations and CFO, at the Morgan Stanley Global Healthcare Meeting on September 10. The meeting will start at 4:05 p.m. Eastern Daylight Time.
In order to listen to the ‘Live’ video over the web, visit the company’s internet site at www.pfizer.com and click on given link “Morgan Stanley Global Healthcare Conference” in the For Investors segment situated on the lower right-hand area of that page. Data on accessing and pre-registering for the internet cast will be accessible at www.pfizer.com starting today.
Introducing New Advil® Film Coated Tablets – Designed to Stop Pain Before It Gets Worse
Pfizer, the manufacturer of Advil®, declared its newest addition in pain relief – speedily acting Advil® Film Coated tabs. This first-to-market formula marks the entry of Advil Ion Core? Technology in the US zone. This novel, speedily-dissolving technology, together with an exclusive, specially originated ultra-thin coating, is fabricated for pace, going to work in minutes and ending pain in its paths before it turns worse.
The innovative quickly acting Advil® tabs feature a breakthrough, ultra-thin coating, which melts quickly, exhibiting the novel Advil Ion Core? of ibuprofen sodium.
The future of medical marijuana is all about the delivery system. MediJane brings you transdermal patches, Gel Capsules, Sublingual's and topical creams. Learn more about MediJane Holdings, Inc. (OTCQB: MJMD) Click Here Now
“Tough pain escalates if not treated promptly,” stated Brian Groves, U.S. CMO at Pfizer Consumer Healthcare. “Our innovative, speedily acting Advil® tabs are made to end pain in its pathways, before it turns worse and slowdowns the busy lives of our over 100 million Advil® consumers.”
Pfizer Inc.’s Xalkori gets rejected by UK
The company’s lung cancer medicine Xalkori was tentatively disapproved by an advisory group for utilization in the U.K.’s National Health Service.
Claiming the medicine, also known as crizotinib, was very costly, NICE recommended against sanctioning the medicine for utilization in the cash-strapped universal healthcare structure, regardless of the company’s discount offer.